Put Antipsychotics for Agitation in Dementia in Perspective

September 2023

A new indication for brexpiprazole (Rexulti) will raise questions about treating agitation in dementia with antipsychotics.

Brexpiprazole is a second-generation antipsychotic already approved for schizophrenia and as an add-on for depression.

Now you’ll hear that brexpiprazole is the first med FDA-approved for agitation in patients with Alzheimer’s dementia.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote